Flynn James E 13D and 13G filings for Catalyst Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-13 08:57 am Sale |
2024-12-31 | 13G | Catalyst Pharmaceuticals, Inc. CPRX |
Flynn James E | 3,133,011 2.630% |
-3,096,623 (-49.71%) |
Filing |
| 2024-11-14 09:55 am Sale |
2024-09-30 | 13G | Catalyst Pharmaceuticals, Inc. CPRX |
Flynn James E | 6,229,634 5.220% |
-2,659,267 (-29.92%) |
Filing |
| 2024-02-12 5:31 pm Purchase |
2023-12-31 | 13G | Catalyst Pharmaceuticals, Inc. CPRX |
Flynn James E | 8,888,901 8.340% |
3,004,453 (+51.06%) |
Filing |
| 2023-02-10 09:28 am Sale |
2022-12-31 | 13G | Catalyst Pharmaceuticals, Inc. CPRX |
Flynn James E | 5,884,448 5.650% |
-176,043 (-2.90%) |
Filing |
| 2022-11-14 4:45 pm Purchase |
2022-11-04 | 13G | Catalyst Pharmaceuticals, Inc. CPRX |
Flynn James E | 6,060,491 5.820% |
6,060,491 (New Position) |
Filing |